吉西他滨联合氟脲嘧啶脱氧核苷治疗晚期原发性肝癌临床研究.pdfVIP

·272· 世界肿瘤袭恚 2007年 第6卷 第4期 Tumour Journal ofthe World Volume 6．Number4．Dec 2007 文章编号：1683—0342(2007)04—0272—02 半论 著 半 吉西他滨联合氟脲嘧啶脱氧核苷治疗晚期原发性肝 癌临床研究 任中海，张成辉，李长生，薛永飞，李 明，张敬伟 摘要：目的 观察吉西他滨(GEM)联合氟脲嘧啶脱氧核苷(FUDR)的FG方案治疗晚期肝癌的临床 效果与不良反应。方法 采用吉西他滨(GEM)联合氟脲嘧啶脱氧核苷(FUDR)治疗 37例晚期原发性 肝癌病人。GEM 1000mg／m ，静脉滴注，30min，dl、d8；FUDR 1000mg／m ，持续静脉滴注，d1、d4； 21d为一个周期。所有病例均至少完成2周期治疗后评价疗效。结果 37例中CR(完全缓解)1例， PR(部分缓解)9例，MR(好转)13例，SD(稳定)8例，PD(进展)6例。RR率27．0％，临床受 益率 (CR+PR+MR+SD)为83．8％。中位生存时间为10．2mo，la生存率43．2％。骨髓抑制以白细胞减 少为主，发生率32．4％。黏膜炎和腹泻 的发生率增加，但均为I～II度，发生率分别为21．6％和29．7％。 结论 FG方案明显延长了病人的生存时间并提高了生活质量。值得临床进一步研究。 关键词：原发性肝癌；吉西他滨；氟脲嘧啶脱氧核苷；化学治疗 中图分类号：R735．7；R730．53 文献标识码：A Clinical study on gemcitabine combined with floxuridine in the treatment of advanced primary liver carcinoma REN Zhong—hai,ZHANG Cheng—hui，LI Chang—sheng，XUE Yong-fei，LI Ming，ZHANG Jing—wei fDepartment of Oncology；Nanyang Center Hospital；Nanyang 473000；He Nan；China) Abstract：Objective To evaluate the clinical efficacy and toxicity of gemcitabine combined with floxuridine in the treatment of advanced primary liver carcinoma．Methods 37 patients with advanced primary liver carcinoma were treated with FG regime(gemcitabine 1000mg／m ，ivgtt，30min，dl+8；and floxuridine 1000mg／m civ,dl，d4)．Twenty—one days were considered as one cycle．The efficacy of patients was evaluated after at least two cycles．Results Th e total response rate of the 37 patients enrolled in this study was 27．0％．CR was one，PR was 9，MR was 13，SD was 8 and PD was 6．Th e clinical profit rate (CR+PR+MR+SD)was 83．8％．The mean survival time for all 37 patients was 10．2 month and the 1-year survival rate Was 43_2％．Myelosuppression Was characteristic of leucocytopenia and the incidence rate was 32．4％．Th e incidence rates of membranitis and diarrhea were 2 1．6％ and 29．7％．Conclusions Th e FG regime Can obviously improve life quality with survival time prolong． Key words：primary liver ca